A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy with Bortezomib (Velcade) in Patients with Multiple Myeloma in First or Second Relapse.
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2017
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMIZED-RETREAT; OPTIMRETREAT
- Sponsors Janssen-Cilag
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Status changed to discontinued.
- 18 Nov 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History